NasdaqGS:BCRXBiotechs
BioCryst (BCRX) Stock Looks Like A Bargain After Facility Closure
BioCryst Pharmaceuticals stock has rebounded in recent years but is still down about 40.0% over five years, which sits alongside valuation checks that currently lean cheap on traditional metrics. With recent news highlighting both a shift toward external innovation and takeover speculation, investors are trying to work out whether the recent strength in the share price is backed by the fundamentals or running ahead of them.
The share price decline of about 40.0% over five years leaves long...